Drugs / Apraclonidine
Apraclonidine
also known as
AL-02145 · Aplonidine hydrochloride · Apraclonidina · Apraclonidine Hcl · Apraclonidine Hydrochloride · Iopidine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | IOPIDINE | — | 1989-12-15 | fda.gov ↗ |
| Approved | US (FDA) | IOPIDINE | — | 1987-12-31 | fda.gov ↗ |
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05045248 | Jun 2020 → Apr 2021 | ocular myasthenia gravis | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07531043 | Oct 2026 → Feb 2027 expected | ocular hyperemia | Alcon Research | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07578363 | Sep 2026 → Mar 2027 expected | ocular hyperemia | Alcon Research | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06444529 | Aug → Nov 2024 | ocular hyperemia | Alcon Research | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05167760 | Dec 2025 → Nov 2027 | cranial nerve neuropathy, facial paralysis | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00567411 Comparator | Aug 2006 → Jun 2009 | ocular hypertension, open-angle glaucoma | Walter Reed Army Medical Center | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apraclonidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05167760 ↗ |
| Known as | AL-02145 | ChEMBL registry synonym — accepted as the source's own label CHEMBL647 ↗ |
| Known as | Aplonidine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL647 ↗ |
| Known as | Apraclonidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL647 ↗ |
| Known as | Apraclonidine Hcl | “Apraclonidine Hcl 0.5% Oph Soln” NCT05045248 ↗ |
| Known as | Apraclonidine Hydrochloride | “A Double-Masked Comparison of Apraclonidine Hydrochloride Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness” NCT06444529 ↗ |
| Known as | Iopidine | “Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT” NCT00567411 ↗ |
| Action | Activate | “Apraclonidine elevates the eyelid by activating alpha-2 receptors on Muller's muscle” PMID 37259693 ↗ May 2023 |
| Modality | Small molecule | — CHEMBL647 ↗ |
| Route | Topical | “one drop of apraclonidine 0.5% in the fellow eye” NCT00567411 ↗ |